Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. (Q55476205)

12 July 2018

title

Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. (English)

1 reference

12 July 2018

author

Qiang Wang

7

1 reference

12 July 2018

Donald M O'Rourke

9

1 reference

12 July 2018

author name string

B W Park

1

1 reference

12 July 2018

H T Zhang

2

1 reference

12 July 2018

C Wu

3

1 reference

12 July 2018

A Berezov

4

1 reference

12 July 2018

X Zhang

5

1 reference

12 July 2018

R Dua

6

1 reference

12 July 2018

G Kao

8

1 reference

12 July 2018

M I Greene

10

1 reference

12 July 2018

R Murali

11

1 reference

12 July 2018

publication date

1 February 2000

1 reference

12 July 2018

published in

Nature Biotechnology

1 reference

12 July 2018

volume

18

1 reference

12 July 2018

issue

2

1 reference

12 July 2018

page(s)

194-198

1 reference

12 July 2018

https://scigraph.springernature.com/pub.10.1038/72651

exact match

0 references

cites work

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

21 January 2018

1 reference

Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene

21 January 2018

1 reference

Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen

21 January 2018

1 reference

Macromolecular versus small-molecule therapeutics: drug discovery, development and clinical considerations

21 January 2018

1 reference

Conformational and topographical considerations in the design of biologically active peptides

21 January 2018

1 reference

Structure-based design of immunologically active therapeutic peptides

21 January 2018

1 reference

Designing peptide mimetics

21 January 2018

1 reference

Therapeutic peptides and peptidomimetics

21 January 2018

1 reference

Design and synthesis of a mimetic from an antibody complementarity-determining region.

21 January 2018

1 reference

Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation.

21 January 2018

1 reference

Antibody-antigen interactions: contact analysis and binding site topography.

21 January 2018

1 reference

The structural basis of antigen-antibody recognition

21 January 2018

1 reference

Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen

21 January 2018

1 reference

X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling

21 January 2018

1 reference

X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: structural indications of the key role of VH residues 59 to 65

21 January 2018

1 reference

Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies

21 January 2018

1 reference

Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes

21 January 2018

1 reference

Phosphinic peptides, the first potent inhibitors of astacin, behave as extremely slow-binding inhibitors

21 January 2018

1 reference

Structure-activity analysis of binding kinetics for NMDA receptor competitive antagonists: the influence of conformational restriction

21 January 2018

1 reference

Characterization of different soluble TNF receptor (TNFR80) derivatives: positive influence of the intracellular domain on receptor/ligand interaction and TNF neutralization capacity.

21 January 2018

1 reference

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

21 January 2018

1 reference

Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill

21 January 2018

1 reference

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

21 January 2018

1 reference

Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells

21 January 2018

1 reference

Solution Structures of FcεRI α-Chain Mimics: A β-Hairpin Peptide and Its Retroenantiomer

21 January 2018

1 reference

Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor

21 January 2018

1 reference

7 January 2021

Canonical structures for the hypervariable regions of immunoglobulins

1 reference

7 January 2021

Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides

1 reference

7 January 2021

Amino acids that specify structure through hydrophobic clustering and histidine-aromatic interactions lead to biologically active peptidomimetics

1 reference

7 January 2021

Identification of p185neu sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation

1 reference

7 January 2021

Cell-cycle arrest versus cell death in cancer therapy

1 reference

7 January 2021

Prevention of breast tumour development in vivo by downregulation of the p185neureceptor

1 reference

7 January 2021

Identifiers

DOI

10.1038/72651

1 reference

12 July 2018

Dimensions Publication ID

0 references

1 reference

12 July 2018